

Registered number: 733512

BIOTECH LIFESCIENCES LIMITED

UNAUDITED

ABRIDGED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

BIOTECH LIFESCIENCES LIMITED

CONTENTS

	Page
Company information	1
Directors' responsibilities statement	2
Accountants' report	3
Abridged statement of financial position	4 - 5
Statement of changes in equity	6 - 7
Notes to the abridged financial statements	8 - 13

BIOTECH LIFESCIENCES LIMITED

COMPANY INFORMATION

Directors	Mehul Pratap Asnani Ruchira Asnani
Company secretary	Mehul Pratap Asnani
Registered number	733512
Registered office	Zone 3, Unit 3 Roscommon Business & Technology Park Race Course Road Co. Roscommon
Accountants	RBK Business Advisers Chartered Accountants RBK House Irishtown Athlone Co. Westmeath
Bankers	Bank of Ireland Main Street Co. Roscommon

BIOTECH LIFESCIENCES LIMITED

**DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 MARCH 2025**

The directors are responsible for preparing the Directors' report and the financial statements in accordance with Irish law and regulations.

Irish company law requires the directors to prepare the financial statements for each financial year. Under the law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', applying Section 1A of that Standard, issued by the Financial Reporting Council and promulgated by the Institution of Chartered Accountants in Ireland.

Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the Company as at the financial year end date, of the profit or loss for that financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the Company's financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.


The directors are responsible for ensuring that the Company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the Company, enable at any time the assets, liabilities, financial position and profit or loss of the Company to be determined with reasonable accuracy and enable them to ensure that the financial statements and Directors' report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Directors' declaration on unaudited financial statements


In relation to the financial statements as set out on pages 5 to 14:

- The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies for the Company's financial statements, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on a going concern basis on the grounds that the Company will continue in business.
- The directors confirm that they have made available to RBK Business Advisers, all the Company's accounting records and provided all the information necessary for the compilation of the financial statements.
- The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the Company for the year ended 31 March 2025.

On behalf of the board



Mehul Pratap Asnani
Director
Date: 19 December 2025



Ruchira Asnani
Director
Date: 19 December 2025

BIOTECH LIFESCIENCES LIMITED

**CHARTERED ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS ON THE UNAUDITED
FINANCIAL STATEMENTS OF BIOTECH LIFESCIENCES LIMITED
FOR THE YEAR ENDED 31 MARCH 2025**

In order to assist you to fulfil your duties under the Companies Act 2014, we have compiled the financial statements of Biotech Lifesciences Limited for the year ended 31 March 2025 which comprise the Statement of financial position, the Statement of changes in equity and the related notes from the Company's accounting records and from information and explanations you have given us.

This report is made solely to the Board of directors of Biotech Lifesciences Limited, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely so that we might compile the financial statements of Biotech Lifesciences Limited that we have been engaged to compile, report to the Company's Board of Directors that we have done so and state those matters that we have agreed to state to the Board of directors of Biotech Lifesciences Limited, as a body, in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Biotech Lifesciences Limited and its Board of directors, as a body, for our work or for this report.

We have carried out this engagement in accordance with technical guidance issued by the Institute of Chartered Accountants in Ireland and have complied with the ethical guidance laid down by the Institute relating to members undertaking the compilation of financial statements.

You have acknowledged on the Statement of financial position as at 31 March 2025 your duty to ensure that Biotech Lifesciences Limited has kept proper accounting records and to prepare financial statements that give a true and fair view under the Companies Act 2014 of Biotech Lifesciences Limited. You consider that Biotech Lifesciences Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit of the financial statements of Biotech Lifesciences Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the financial statements.

RBK Business Advisers

RBK Business Advisers
Chartered Accountants
RBK House
Irishtown
Athlone
Co. Westmeath
19 December 2025

BIOTECH LIFESCIENCES LIMITED

**ABRIDGED STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2025**

	Note	2025 €	2024 €
Fixed assets			
Tangible assets	5	4,446,082	237,427
		<u>4,446,082</u>	<u>237,427</u>
Current assets			
Debtors: amounts falling due within one year	6	3,938,235	3,115,316
Cash at bank and in hand		5,029	16,645
		<u>3,943,264</u>	<u>3,131,961</u>
Creditors: amounts falling due within one year	7	(387,527)	-
Net current assets		<u>3,555,737</u>	<u>3,131,961</u>
Total assets less current liabilities		<u>8,001,819</u>	<u>3,369,388</u>
Creditors: amounts falling due after more than one year	8	(8,578,595)	(3,515,561)
Net liabilities		<u>(576,776)</u>	<u>(146,173)</u>
Capital and reserves			
Called up share capital presented as equity		1,000	1,000
Profit and loss account		(577,776)	(147,173)
Shareholders' funds		<u>(576,776)</u>	<u>(146,173)</u>

BIOTECH LIFESCIENCES LIMITED

**ABRIDGED STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 MARCH 2025**

We, as directors of Biotech Lifesciences Limited, state that:

- (a) these financial statements have been prepared in accordance with the small companies regime.
- (b) the Company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014.
- (c) the Company is availing itself of the exemption on the grounds that the conditions specified in section 359 are satisfied.
- (d) the members of the Company have not served a notice on the Company under section 334(1) in accordance with section 334(2).
- (e) We acknowledge the Company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the state of the assets, liabilities and financial position of the Company at the end of its financial year and of its profit or loss for such a year and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the Company.
- (f) the Company has relied on the specific exemptions contained in section 352 of the Companies Act 2014; the Company has done so on the grounds that it is entitled to the benefit of that exemption as a small Company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

The financial statements were approved and authorised for issue by the board:

Mehul Pratap Asnani
Director
Date: 19 December 2025

Ruchira Asnani
Director
Date: 19 December 2025

The notes on pages 8 to 13 form part of these financial statements.

BIOTECH LIFESCIENCES LIMITED

**STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2025**

	Called up share capital	Profit and loss account	Total equity
	€	€	€
At 1 April 2024	1,000	(147,173)	(146,173)
Comprehensive income for the year			
Loss for the year	-	(430,603)	(430,603)
Other comprehensive income for the year	-	-	-
Total comprehensive income for the year	-	(430,603)	(430,603)
Total transactions with owners	-	-	-
At 31 March 2025	1,000	(577,776)	(576,776)

The notes on pages 8 to 13 form part of these financial statements.

BIOTECH LIFESCIENCES LIMITED

**STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2024**

	Called up share capital €	Profit and loss account €	Total equity €
Comprehensive income for the period			
Loss for the period	-	(147,173)	(147,173)
Other comprehensive income for the period	-	-	-
Total comprehensive income for the period	-	(147,173)	(147,173)
Contributions by and distributions to owners			
Shares issued during the period	1,000	-	1,000
Total transactions with owners	1,000	-	1,000
At 31 March 2024	1,000	(147,173)	(146,173)

The notes on pages 8 to 13 form part of these financial statements.

BIOTECH LIFESCIENCES LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

1. General information

These financial statements comprising of the Statement of Comprehensive Income, the Statement of Financial Position, the Statement of Changes in Equity and the related notes constitute the individual financial statements of Biotech Lifesciences Limited for the year ended 31 March 2025.

Biotech Lifesciences Limited is a private company limited by shares, incorporated in the Republic of Ireland. The company registration number is 733512. The registered address is Zone 3, Unit 3, Roscommon Business & Technology Park, Race Course Road, Co. Roscommon. The nature of the company's operations and its principal activities are set out in the Director's Report.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2014. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

2.2 Going concern

As at the balance sheet date, the company has a balance sheet deficit of €576,776.

The financial statements are prepared on a going concern basis which assumes the company will continue in operational existence for the foreseeable future.

Having made enquiries and considering the impact noted above the Directors continue to adopt the going concern basis in preparing the financial statements, which assumes that the company will continue in operational existence and liabilities will be discharged as they fall due for the foreseeable future which is 12 months from the date of signing the financial statements. The Directors have reviewed current year management accounts and prepared projections including cashflows for a period up to 12 months from the date of signing the financial statements. Additionally, the Directors note that the parent undertaking has confirmed that it will continue to provide financial support to the company for a period of at least 12 months from the date of signing the financial statements.

Based on the above, the Directors believe it appropriate to prepare the financial statements on a going concern basis.

BIOTECH LIFESCIENCES LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

2. Accounting policies (continued)

2.3 Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is Euros.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of comprehensive income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

2.4 Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

2.5 Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

2.6 Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

BIOTECH LIFESCIENCES LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

2. Accounting policies (continued)

2.6 Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation has not been provided during the year because the assets were not put into use.

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

2.7 Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.8 Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

2.9 Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.

2.10 Cash flow statement exemption

The company has availed of the exemption contained in Section 1A of FRS 102 and as a result have elected not to prepare a cash flow statement.

3. Loss on ordinary activities before taxation

The operating loss is stated after charging:

	2025	2024
	€	€
Exchange differences	(156)	5,539

BIOTECH LIFESCIENCES LIMITED

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

4. Employees

The Company has no employees other than the directors, who did not receive any remuneration (2024 - €NIL).

5. Tangible fixed assets

	Freehold property €	Plant and machinery €	Fixtures and fittings €	Total €
Cost or valuation				
At 1 April 2024	-	237,427	-	237,427
Additions	2,226,487	1,970,250	11,918	4,208,655
At 31 March 2025	<u>2,226,487</u>	<u>2,207,677</u>	<u>11,918</u>	<u>4,446,082</u>
Net book value				
At 31 March 2025	<u>2,226,487</u>	<u>2,207,677</u>	<u>11,918</u>	<u>4,446,082</u>
At 31 March 2024	<u>-</u>	<u>237,427</u>	<u>-</u>	<u>237,427</u>

BIOTECH LIFESCIENCES LIMITED

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

6. Debtors

	2025	2024
	€	€
Other debtors	3,801,876	3,075,316
VAT repayable	96,359	-
Prepayments	40,000	40,000
	<u>3,938,235</u>	<u>3,115,316</u>

7. Creditors: Amounts falling due within one year

	2025	2024
	€	€
Trade creditors	12,189	-
Amounts owed to related parties	150,000	-
Accruals	225,338	-
	<u>387,527</u>	<u>-</u>

8. Creditors: Amounts falling due after more than one year

	2025	2024
	€	€
Amounts owed to related parties	8,578,595	3,515,561
	<u>8,578,595</u>	<u>3,515,561</u>

9. Capital commitments

The company held no capital commitments as at the year end.

10. Related party transactions

The company has availed of the exemption contained within FRS 102 from the requirement to disclose transactions with fellow group companies who are wholly owned by members of the same group.

As at the year end, the company owes €150,000 (2024: Nil) to Biotech Meditech Europe Inc. Limited and €8,578,595 (2024: €3,515,561) to Biotech Healthcare Holding GMBH. Both companies are incorporated in India and both are related by virtue of common directors and shareholders.